Ian Kramer

Finding a Cure for the Cost of Durable Therapies

Dan Mendelson, Yvonne Greenstreet, Joe Grogan, Michael Sherman, Mark Skinner, John Birch, Ian Kramer, Jupiter Lazmar

A panel of industry leaders, payers, and advocates highlighted the systemic friction between transformative gene therapies and traditional commercial models that rely on high-volume patient pools to amortize R&D costs. Participants detailed pricing pressures for one-time cures and chronic durable treatments while showcasing innovative risk-sharing agreements, such as Alnylam's outcomes-based pilot with Harvard Pilgrim Health Care, to manage financial exposure. Addressing these challenges, the group called for federal policy reform to eliminate "best price" disincentives and the adoption of flexible valuation frameworks that integrate patient-reported outcomes to prevent insurance affordability crises.